As life expectancy increases in patients with advanced cancer, various complications may occur. Malignant biliary obstruction is one of the representative complications, which is caused by primary bile duct cancer, peribiliary metastasis, or metastases of liver and lymph nodes. Currently, surgical methods are rarely used for bile duct drainage, and less invasive procedures, including endoscopic or radiologic approaches are mainly performed. ERCP-assisted biliary drainage is the primary method for palliation of malignant biliary obstruction, and percutaneous approach is an alternative method when ERCP fails. However, with the recent advance of EUS interventions, EUS-guided biliary drainage is replacing the percutaneous approach, and sometimes provided as an initial drainage method in some institutions. We need to review the pros and cons of each bile duct drainage method in detail and organize which procedure will be most helpful to the patient in which situation. Besides drainage methods, we need to redefine the timing and indication of biliary drainage, and standardization of drainage procedures and devices.
The goal of this Research Topic is to look at the recent clinical advances and controversial issues in the management of malignant biliary obstruction. Through this, a standardized treatment for malignant biliary obstruction can be suggested.
We welcome the submission of Original Research and Review Articles covering, but not limited, to the following sub-topics:
-The pros and cons of ERCP, Radiologic, and EUS-guided biliary drainage
-The indication and optimal timing of biliary drainage
-Ideal biliary drainage method according to cancer type
-Novel procedures and devices for the palliation of malignant biliary obstruction
-Future perspectives for a longer-lasting and effective biliary drainage
Please note: manuscripts consisting solely of bioinformatics or computational analysis of public genomic or transcriptomic databases which are not accompanied by validation (independent cohort or biological validation in vitro or in vivo) are out of scope for this section and will not be accepted as part of this Research Topic.
As life expectancy increases in patients with advanced cancer, various complications may occur. Malignant biliary obstruction is one of the representative complications, which is caused by primary bile duct cancer, peribiliary metastasis, or metastases of liver and lymph nodes. Currently, surgical methods are rarely used for bile duct drainage, and less invasive procedures, including endoscopic or radiologic approaches are mainly performed. ERCP-assisted biliary drainage is the primary method for palliation of malignant biliary obstruction, and percutaneous approach is an alternative method when ERCP fails. However, with the recent advance of EUS interventions, EUS-guided biliary drainage is replacing the percutaneous approach, and sometimes provided as an initial drainage method in some institutions. We need to review the pros and cons of each bile duct drainage method in detail and organize which procedure will be most helpful to the patient in which situation. Besides drainage methods, we need to redefine the timing and indication of biliary drainage, and standardization of drainage procedures and devices.
The goal of this Research Topic is to look at the recent clinical advances and controversial issues in the management of malignant biliary obstruction. Through this, a standardized treatment for malignant biliary obstruction can be suggested.
We welcome the submission of Original Research and Review Articles covering, but not limited, to the following sub-topics:
-The pros and cons of ERCP, Radiologic, and EUS-guided biliary drainage
-The indication and optimal timing of biliary drainage
-Ideal biliary drainage method according to cancer type
-Novel procedures and devices for the palliation of malignant biliary obstruction
-Future perspectives for a longer-lasting and effective biliary drainage
Please note: manuscripts consisting solely of bioinformatics or computational analysis of public genomic or transcriptomic databases which are not accompanied by validation (independent cohort or biological validation in vitro or in vivo) are out of scope for this section and will not be accepted as part of this Research Topic.